An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII

Anesthesia and Analgesia

Volumn 93, Issue 2, 2001, Pages 287-289

  Hendriks, Herman G D ^a   Van Der Maaten, Joost M A A ^a   De Wolf, Joost ^a   Waterbolk, Tjalling W ^a   Slooff, Maarten J H ^a   Der Meer, Janvan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CASE REPORT; DRUG INDUCED DISEASE; HEART VALVE SURGERY; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034914327     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200108000-00009     Document Type: Article

References (13)

1. Factors associated with excessive post operative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients
2. Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors
3. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations
4. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
5. Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques
6. Clinical experience with recombinant factor VIIa
7. Recombinant activated factor VII as a universal haemostatic agent
8. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation, a pilot study
9. Overall experience with NovoSeven®
10. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery
11. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
12. Platelet activity of high-dose factor VIIa is independent of tissue factor
13. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders